Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZLI versus tobramycin nebuliser solution in cystic fibrosis with Pseudomonas aeruginosa infection
2007-004277-26Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aztreonam and tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection (3 arms), sponsored by Gilead Sciences. Primary endpoint: Relative change from baseline in FEV1 percent predicted at Day 28. Started Dec 2007; status: completed.
02
Drugs
aztreonamtobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2007-004277-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004277-26.